INSV Insite Vision Inc. featured news, full reports, and detailed charts
Insite Vision Inc. (INSV/INSV.OB) Wrap Up:
InSite Vision Incorporated operates as an ophthalmic product development company in the United States. It engages in the development and commercialization of ophthalmic pharmaceutical products based on DuraSite drug delivery technology. The company offers AzaSite for the treatment of bacterial conjunctivitis. It develops ISV-502, which completed Phase III (a) clinical trial for the treatment of blepharoconjunctivitis, an infection of the eyelid and the conjunctiva, as well as other ophthalmic infections; and ISV-405, a preclinical development candidate for the treatment of ocular infection. InSite Vision Incorporated has collaborative, licensing, and service agreements with Shin Poong Pharm Co., Ltd.; Bioceutica S.A.; Biem Pharmaceuticals; Essex Bio-Technology; Pfizer Inc. and Pfizer Products, Inc.; and Inspire Pharmaceuticals, Inc.; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. The company was founded in 1986 and is based in Alameda, California.Insite Vision Inc. (INSV:OTC Bulletin Board Market)
Snapshot of Insite Vision Inc. (INSV)
|
OPEN
$0.39
|
PREVIOUS CLOSE
$0.38
|
|
|
DAY HIGH
$0.40
|
DAY LOW
$0.38
|
|
|
52 WEEK HIGH
06/3/09 - $0.66
|
52 WEEK LOW
03/5/09 - $0.11
|
|
|
MARKET CAP
36.9M
|
AVERAGE VOLUME 3 mo
83.7K
|
|
|
DILUTED EPS TTM
$-0.22
|
SHARES OUTSTANDING
94.7M
|
|
|
INSV Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
INSV Top Compensated Officers
Executives, Board Directors
Key developments for Insite Vision Inc. (INSV)
On November 11, InSite Vision, Inc. reported its financial results on Wednesday for the third quarter ended September 30, 2009 with revenues of $2.2 million compared to $1.0 million for the same period in 2008. The company is looking for potential products, technologies or merger/acquisition opportunities. Louis Drapeau, CEO of InSite Vision said: "We remain in active discussions with potential commercial partners in Europe and elsewhere for AzaSite. We currently have licensing and distribution agreements with partners in Japan, Taiwan, South Korea, four countries in South America, Turkey and China. We expect the first international commercial launch of AzaSite to occur in the first half of 2010." He added: "We have been working with our advisor, Piper Jaffray, to facilitate the identification and evaluation of potential products, technologies or merger/acquisition opportunities. We have narrowed our evaluation of potential collaboration opportunities to a select few. We will provide future updates, as appropriate."
Insite Vision Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net loss of $3,052,000 or $0.03 per basic and diluted share on revenue of $2,209,000 against net loss of $7,950,000 or $0.08 per basic and diluted share on revenue of $960,000 for the same period a year ago. Loss from operations of $539,000 compared to $5,625,000 for the same period a year ago. For the nine months, the company reported net loss of $12,107,000 or $0.13 per basic and diluted share on revenue of $6,336,000 against net loss of $12,742,000 or $0.13 per basic and diluted share on revenue of $12,196,000 for the same period a year ago. Loss from operations of $4,622,000 compared to $7,195,000 for the same period a year ago.
Insite Vision Inc., Q3 2009 Earnings Call, Nov 11 2009
INSV Competitors
| Company | Last | Change |
| Curis Inc | $2.26 USD | -0.03 |
| Insmed Inc | $0.79 USD | 0.00 |
| Peregrine Pharmaceuticals Inc | $2.95 USD | -0.07 |
| Vical Inc | $3.07 USD | -0.11 |
| Vion Pharmaceuticals Inc | $0.61 USD | +0.03 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | INSV | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.7x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
INSV |
||
INSV transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
